The median IgA level in the convalescent-phase serum samples increased approximately twofold (1.61, IQR = 1.00–2.61) and significantly higher than the acute serum samples (0.98, IQR = 0.88–1.02) of COVID-19 patients (P = 0.009, Fig 3B). This evidence concerns the gene CD79A and COVID-19.